E Fund Management’s Viridian Therapeutics VRDN Stock Holding History

E Fund Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Sell	15,334 -2,513	-14%	-$40.5K	0.01%	391
2026 Q1	$349K	Buy	+17,847	New	+$530K	0.01%	356
2025 Q1	–	Sell	-12,236	Closed	-$235K	–	435
2024 Q4	$235K	Buy	+12,236	New	+$266K	0.01%	345
2024 Q2	–	Sell	-19,323	Closed	-$338K	–	382
2024 Q1	$338K	Buy	19,323 +8,448	+78%	+$164K	0.02%	259
2023 Q4	$237K	Sell	10,875 -2,562	-19%	-$40.4K	0.02%	258
2023 Q3	$206K	Buy	13,437 +315	+2%	+$6.01K	0.02%	255
2023 Q2	$312K	Buy	13,122 +3,078	+31%	+$79K	0.02%	214
2023 Q1	$256K	Buy	+10,044	New	+$322K	0.02%	260

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

E Fund Management's VRDN Position: Q2 2026 in Review

E Fund Management reduced its Viridian Therapeutics (VRDN) stake by 14% in Q2 2026, selling an estimated $40.5K and leaving 15,334 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #391.

E Fund Management first reported a position in VRDN in Q1 2023 and has held it in 8 quarters since. The position peaked at $349K in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

E Fund Management held 15,334 shares of Viridian Therapeutics worth $282K as of Q2 2026.
E Fund Management sold 2,513 Viridian Therapeutics shares in Q2 2026, an estimated $40.5K.
Viridian Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #391 holding.
E Fund Management first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 8 quarters since.
E Fund Management's Viridian Therapeutics position peaked at $349K in Q1 2026.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.